^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    onvatilimab (CI-8993)

    i
    Other names: CI-8993, JNJ-61610588, JNJ 61610588, CI 8993, CI8993, VSTB112, VSTB 112, VSTB-112, JNJ61610588
    Associations

    News

    Trials
    Company:
    Curis, ImmuNext
    Drug class:
    VISTA antagonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade. (PubMed, Front Immunol)
    The bsAbs generated in this study showed weaker binding properties to PD-1 and VISTA in ELISA (EC50) than the parent antibodies (atezolizumab and onvatilimab). Both the asymmetric and symmetric bsAbs resulted in higher secretion levels of IFN-γ, TNFα and Granzyme B than anti-VISTA, anti-PD-L1 monotherapy and anti-VISTA/anti-PD-L1 combination therapy. The high level of tumor cell lysis and increased expression of pro-inflammatory cytokines induced by the Fc-based bsAbs suggest a novel approach for the treatment of pancreatic, endometrial and breast cancer.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • GZMB (Granzyme B)
    |
    Tecentriq (atezolizumab) • onvatilimab (CI-8993)
    12ms
    METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer. (PubMed, J Immunother Cancer)
    We elucidate that an underappreciated function of truncated APC in CRC is its ability to drive an immunosuppressive program that boosts tumor progression. Our work could provide a new perspective for the clinical application of immunotherapy in patients with CRC resistant to ICB therapy.
    Journal • IO biomarker
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • APC (APC Regulator Of WNT Signaling Pathway) • METTL3 (Methyltransferase Like 3)
    |
    APC mutation • HIF1A expression
    |
    onvatilimab (CI-8993)
    over1year
    Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993. (PubMed, Eur J Nucl Med Mol Imaging)
    We radiolabelled and validated [89Zr]Zr-Df-CI-8993 for specific binding to huVISTA in vivo. Our results demonstrate that 89Zr-labelled CI-8993 is now suitable for targeting and imaging VISTA expression in human trials.
    Journal
    |
    VSIR (V-Set Immunoregulatory Receptor)
    |
    onvatilimab (CI-8993)
    2years
    CI-8993-101: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=26, Completed, Curis, Inc. | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    onvatilimab (CI-8993)